Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ANGLE plc specializes in the development of liquid biopsy technologies for cancer diagnostics, with its flagship product, the Parsortix system, enabling the capture and analysis of circulating tumor cells (CTCs). The company operates primarily in the UK and the US, targeting a growing market for non-invasive cancer diagnostics, which is driven by increasing cancer prevalence and demand for early detection.
ANGLE generates revenue primarily through the sale of its Parsortix systems and associated consumables, which have high gross margins of 62.2%. The company has established a competitive advantage through its proprietary technology that allows for the efficient capture of CTCs, which is critical for cancer diagnostics. Its pricing power is supported by the growing demand for non-invasive testing methods.
Regulatory approvals for new applications of the Parsortix system
Partnership announcements with major healthcare providers
Clinical trial results demonstrating the efficacy of CTC analysis
Market expansion into new geographies, particularly in the US and Europe
Technological disruption from emerging diagnostic technologies
Regulatory changes affecting the approval process for medical devices
Increased competition from established players in the liquid biopsy market
Potential for new entrants with innovative technologies
Liquidity risk due to negative cash flow and reliance on external financing
Potential dilution risk if additional equity financing is required
moderate - The demand for cancer diagnostics can be influenced by overall healthcare spending, which is correlated with GDP growth.
Minimal impact as the company is not heavily reliant on debt financing; however, higher rates could affect the availability of capital for growth initiatives.
minimal
growth - Investors looking for exposure to innovative healthcare technologies and potential high returns from market expansion.
high - The stock has shown significant price volatility, evidenced by a 90.8% decline over the past year.